Roles of miRNAs in Colorectal Cancer: Therapeutic Implications and Clinical Opportunities

Amir Mehrgou ¹ , Shima Ebadollahi ², Khaled Seidi ³, Mohammad Hosein Ayoubi-Joshaghani ^4,5, Amirhossein Ahmadieh Yazdi ⁶, Peyman Zare ^7,8, Mehdi Jaymand ⁹ * , Rana Jahanban-Esfahlan ^10,11 *

Cited by CrossRef: 5

1- Sharifi-Azad M, Fathi M, Cho W, Barzegari A, Dadashi H, Dadashpour M, Jahanban-Esfahlan R. Recent advances in targeted drug delivery systems for resistant colorectal cancer. Cancer Cell Int. 2022;22(1) [Crossref]

2- Kaveh Zenjanab M, Hashemzadeh N, Alimohammadvand S, Sharifi-Azad M, Dalir Abdolahinia E, Jahanban-Esfahlan R. Notch Signaling Suppression by Golden Phytochemicals: Potential for Cancer Therapy. Adv Pharm Bull. 2024;14(2):302 [Crossref]

3- Fawzy M, Hassan H, Sedky N, Nafie M, Youness R, Fahmy S. Revolutionizing cancer therapy: nanoformulation of miRNA-34 – enhancing delivery and efficacy for various cancer immunotherapies: a review. Nanoscale Adv. 2024;6(21):5220 [Crossref]

4- Niemira M, Bielska A, Chwialkowska K, Raczkowska J, Skwarska A, Erol A, Zeller A, Sokolowska G, Toczydlowski D, Sidorkiewicz I, Mariak Z, Reszec J, Lyson T, Moniuszko M, Kretowski A. Circulating serum miR-362-3p and miR-6721-5p as potential biomarkers for classification patients with adult-type diffuse glioma. Front Mol Biosci. 2024;11 [Crossref]